| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $809,527 | 5 | 100 |
| Hubbard Cristin | EVP, Chief Commercial Officer | 0 | $0 | 1 | $17,723 | $-17,723 |
| Burkhart Erin | GVP, Chief Accounting Officer | 0 | $0 | 3 | $290,449 | $-290,449 |
| Guyer Charles Greg | EVP, Chief Technical Officer | 0 | $0 | 1 | $501,355 | $-501,355 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $809,527 worth of BioMarin Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $314,469 and sold $17.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.
| 2025-05-20 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 1,786 0.0009% | $59.31 | $105,928 | -7.21% | |
| 2025-05-02 | Sale | Hubbard Cristin | EVP, Chief Commercial Officer | 273 0.0001% | $64.92 | $17,723 | -9.39% | |
| 2025-03-19 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 1,295 0.0007% | $71.52 | $92,618 | -19.85% | |
| 2025-03-06 | Sale | Guyer Charles Greg | EVP, Chief Technical Officer | 7,034 0.0037% | $71.28 | $501,355 | -19.51% | |
| 2025-02-24 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 1,344 0.0007% | $68.38 | $91,903 | -16.73% | |
| 2024-11-12 | Sale | Guyer Charles Greg | EVP, Chief Technical Officer | 5,278 0.0028% | $66.37 | $350,324 | -10.30% | |
| 2024-08-13 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 714 0.0004% | $90.00 | $64,260 | -28.28% | |
| 2024-05-30 | Sale | Mueller Brian | EVP, Chief Financial Officer | 5,000 0.0027% | $75.19 | $375,950 | -7.26% | |
| 2024-05-28 | Sale | Davis George Eric | EVP, Chief Legal Officer | 40,850 0.0215% | $74.51 | $3.04M | -6.91% | |
| 2024-05-10 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $81.14 | $1.62M | -13.49% | |
| 2024-05-09 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $81.62 | $1.63M | -14.21% | |
| 2024-05-02 | Sale | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 5,000 0.0026% | $82.91 | $414,550 | -16.14% | |
| 2024-05-02 | Sale | Davis George Eric | EVP, Chief Legal Officer | 1,850 0.001% | $85.01 | $157,269 | -16.14% | |
| 2024-04-12 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0104% | $91.26 | $1.83M | -23.17% | |
| 2024-04-11 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $90.99 | $1.82M | -22.35% | |
| 2024-04-10 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 2,286 0.0012% | $90.00 | $205,740 | -21.14% | |
| 2024-03-28 | Sale | Davis George Eric | EVP, Chief Legal Officer | 24,602 0.0132% | $88.34 | $2.17M | -18.18% | |
| 2024-03-06 | Sale | BIENAIME JEAN JACQUES | director | 1,000 0.0005% | $86.71 | $86,713 | -11.92% | |
| 2024-03-05 | Sale | BIENAIME JEAN JACQUES | director | 1,000 0.0005% | $85.51 | $85,510 | -10.82% | |
| 2024-03-05 | Sale | FUCHS HENRY J | President, Worldwide R&D | 35,341 0.0186% | $85.18 | $3.01M | -10.82% |
| Guyer Charles Greg | EVP, Chief Technical Officer | 87655 0.0456% | $4.68M | 0 | 4 | |
| Hubbard Cristin | EVP, Chief Commercial Officer | 32700 0.017% | $1.75M | 0 | 1 | |
| Burkhart Erin | GVP, Chief Accounting Officer | 14173 0.0074% | $756,838.20 | 0 | 5 | |
| WILLIAMS GWYNN | director | 812565 0.423% | $43.39M | 0 | 8 | |
| BIENAIME JEAN JACQUES | director | 474994 0.2472% | $25.36M | 26 | 321 | +29.88% |
| STARR CHRISTOPHER M | SVP, Chief Scientific Officer | 295176 0.1536% | $15.76M | 0 | 7 | |
| FUCHS HENRY J | President, Worldwide R&D | 212117 0.1104% | $11.33M | 0 | 72 | |
| MEIER RICHARD A | 104032 0.0542% | $5.56M | 4 | 9 | +42.46% | |
| PRICE FREDRIC D | Chief Executive Officer | 79285 0.0413% | $4.23M | 1 | 0 | <0.0001% |
| Mueller Brian | EVP, Chief Financial Officer | 72159 0.0376% | $3.85M | 2 | 32 | +36.78% |
| BAFFI ROBERT | EVP, Technical Operations | 71882 0.0374% | $3.84M | 8 | 30 | +11.93% |
| Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 66767 0.0348% | $3.57M | 0 | 66 | |
| ASELAGE STEVE | EVP, Chief Business Officer | 59030 0.0307% | $3.15M | 7 | 25 | +10.2% |
| Davis George Eric | EVP, Chief Legal Officer | 56157 0.0292% | $3M | 4 | 73 | +5.04% |
| SPIEGELMAN DANIEL K | EVP, Chief Financial Officer | 47510 0.0247% | $2.54M | 0 | 33 | |
| GREY MICHAEL G | director | 42840 0.0223% | $2.29M | 0 | 7 | |
| HERON ELAINE J | director | 41685 0.0217% | $2.23M | 0 | 7 | |
| Cooper Jeffrey H | SVP, Chief Financial Officer | 41089 0.0214% | $2.19M | 4 | 26 | <0.0001% |
| KAKKIS EMIL D | Chief Medical Officer | 39621 0.0206% | $2.12M | 6 | 14 | +3.16% |
| KLEIN JOSEPH III | director | 35000 0.0182% | $1.87M | 3 | 4 | +42.82% |
| PYOTT DAVID E I | director | 30740 0.016% | $1.64M | 1 | 0 | +0.47% |
| LAPALME PIERRE | director | 30150 0.0157% | $1.61M | 4 | 6 | +9.26% |
| LAWLIS V BRYAN | director | 28950 0.0151% | $1.55M | 0 | 28 | |
| Slamon Dennis | director | 21639 0.0113% | $1.16M | 0 | 1 | |
| LEWIS ALAN | director | 21160 0.011% | $1.13M | 0 | 8 | |
| Wood Mark | VP, Human Resources | 20277 0.0106% | $1.08M | 1 | 89 | +66.1% |
| Dere Willard H | director | 13290 0.0069% | $709,686.00 | 0 | 1 | |
| Alles Mark J | director | 10905 0.0057% | $582,327.00 | 1 | 0 | +6.53% |
| Swiedler Stuart J | SVP, Clinical Affairs | 10000 0.0052% | $534,000.00 | 0 | 11 | |
| SAGER ERICH | director | 3309 0.0017% | $176,700.60 | 0 | 6 | |
| URQUHART JOHN | director | 0 0% | $0 | 0 | 1 |
$159,914,414 | 243 | 18.52% | $9.06B | |
$211,610,344 | 91 | 38.45% | $12.8B | |
BioMarin Pharmaceutical Inc. (BMRN) | $2,765,836 | 72 | 20.00% | $10.26B |
$108,876,545 | 67 | 72.81% | $7.45B | |
$88,307,390 | 38 | -1.70% | $10.31B | |
$19,233,721 | 36 | 70.14% | $11.89B | |
$1,801,511 | 23 | 18.58% | $8.49B | |
$415,090,639 | 19 | -14.04% | $14.03B | |
$143,065,458 | 17 | 8.01% | $15.4B | |
$11,859,102 | 17 | 18.62% | $7.81B | |
$1,279,017 | 16 | 51.12% | $7.52B | |
$128,181,928 | 16 | 18.84% | $7.29B | |
$627,701,115 | 15 | 145.68% | $13.63B | |
$103,741 | 9 | 49.60% | $12.98B | |
$948,235 | 8 | 15.56% | $9.67B | |
$105,414,951 | 5 | 10.07% | $7.97B | |
$40,276,273 | 4 | 34.57% | $14.58B | |
$36,900,000 | 3 | -9.12% | $9.4B | |
$999,989 | 1 | 262.16% | $10.82B |
| Increased Positions | 312 | +49.13% | 17M | +9.18% |
| Decreased Positions | 281 | -44.25% | 21M | -11.2% |
| New Positions | 76 | New | 3M | New |
| Sold Out Positions | 78 | Sold Out | 2M | Sold Out |
| Total Postitions | 666 | +4.88% | 183M | -2.02% |
| Blackrock, Inc. | $1.23M | 11.48% | 22.05M | -2M | -8.15% | 2025-09-30 |
| Vanguard Group Inc | $1.04M | 9.68% | 18.58M | -421,247 | -2.22% | 2025-09-30 |
| Primecap Management Co/Ca/ | $851,774.00 | 7.93% | 15.23M | -542,886 | -3.44% | 2025-09-30 |
| Dodge & Cox | $821,433.00 | 7.65% | 14.69M | -421,509 | -2.79% | 2025-09-30 |
| State Street Corp | $490,204.00 | 4.57% | 8.76M | -83,152 | -0.94% | 2025-09-30 |
| Viking Global Investors Lp | $465,459.00 | 4.33% | 8.32M | -4M | -32.28% | 2025-09-30 |
| Aqr Capital Management Llc | $331,783.00 | 3.09% | 5.93M | +351,536 | +6.3% | 2025-09-30 |
| Geode Capital Management, Llc | $198,111.00 | 1.85% | 3.54M | +67,682 | +1.95% | 2025-09-30 |
| Millennium Management Llc | $146,940.00 | 1.37% | 2.63M | -207,145 | -7.31% | 2025-09-30 |
| Capital Research Global Investors | $141,928.00 | 1.32% | 2.54M | +2M | +547.55% | 2025-09-30 |